Last reviewed · How we verify

NCT03529058: PORPOISE-REA

Hypophosphatemia as a Predictive Marker of Mortality During Sepsis in ICU

Completed Last updated 18 May 2018
What this trial tests

trial in Hypophosphatemia in 193 participants. Completed in 31 March 2018.

Timeline
26 November 2017
Primary endpoint
31 March 2018
31 March 2018

Quick facts

Lead sponsorUniversity Hospital, Brest
StatusCompleted
Study typeOBSERVATIONAL
Enrollment193
Start date26 November 2017
Primary completion31 March 2018
Estimated completion31 March 2018
Sites1 location across France

Conditions studied

Sponsor

University Hospital, Brest

Who can join

18 and older, any sex, with Hypophosphatemia or Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Retrospective study in the 3 intensive care units of the Brest Teaching Hospital (France) during a 18-months period (June 2014 -December 2015) to study the independent association between hypophosphatemia and 90-day mortality.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Is hypophosphataemia an independent predictor of mortality in critically ill patients with bloodstream infection? A multicenter retrospective cohort study.
    Padelli M, Aubron C, Huet O, Héry-Arnaud G, et al · · 2021 · cited 9× · PMID 32732023 · DOI 10.1016/j.aucc.2020.05.001

Verify or expand the search:

Other recruiting trials for Hypophosphatemia

Currently open trials in the same condition.

Other University Hospital, Brest trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03529058.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing